Sold as Stoxil, Herplex, Dendrid. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 4 applications for Idoxuridine (sold as Stoxil, Herplex, Dendrid), first approved Jun 11, 1963, with 0 new uses approved and 0 published complete response letters.
| Jun 11, 1963 | HerplexNDA 13935 · New molecular entity | Allergan | 19 | Discontinued |
| Jun 28, 1963 | DendridNDA 14169 · New formulation or manufacturer | Alcon | 5 | Discontinued |
| Apr 6, 1964 | StoxilNDA 13934 · New formulation or manufacturer | Glaxosmithkline | 5 | Discontinued |
| Sep 2, 1967 | StoxilNDA 15868 · New dosage form | Glaxosmithkline | 4 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Allergan
Alcon
Glaxosmithkline